Found 18 multiple myeloma trials
A listing of multiple myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Tissue Collection for Multiple Myeloma Research
The primary purpose of this research study is to obtain specimens (blood, bone marrow, and other tissues) for research about multiple myeloma and related diseases.
UPCC 43419: Prospective Study of Immune Biomarkers in Patients with Multiple Myeloma
The objective of this exploratory observational cohort study is to obtain blood samples - and in some cases, bone marrow aspirate samples - from patients with multiple myeloma for study in the laboratory.
Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease (DRAMMATIC Study)
This study will examine whether adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help multiple myeloma patients survive longer. For patients who do not have minimum residual disease [MRD-negative], this study is also trying to determine if maintenance therapy should be stopped after …
UPCC 08423: PHASE 2 SINGLE-ARM NON-INFERIORITY STUDY OF LIMITED-DURATION TECLISTAMAB FOR RELAPSED REFRACTORY MULTIPLE MYELOMA
Phase 2
Please refer to Protocol Section 4 Please refer to Protocol Section 4 Please refer to Protocol Section 4
UPCC 37420 Phase 2 Study of Belantamab Mafodotin As Pre- and Post- Autologous Stem Cell Transplant Consolidation and Maintenance For Multiple Myeloma
Phase 2
The research study is being conducted to see if combining an investigational drug, called belantamab mafodotin, with standard-of-care autologous stem cell transplant and maintenance therapy in patients with myeloma can help reduce the amount of myeloma cells that can be detected in patients after transplant. We will also study if …
UPCC 39422 Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
he purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)
The purpose of this study is to see if JNJ-68284528 is safe and useful for treating patients with relapsed or refractory multiple myeloma.
Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide
We are doing this study to see if CAR T-cell therapy (bb2121) and maintenance therapy with the drug lenalidomide can help delay multiple myeloma from coming back.
UPCC 04423: Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and an Anti-CD38 Antibody
Compassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma. We would like to rely on WCG as the IRB of record for this study.
UPCC 26417: A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients with Refractory Multiple Myeloma
Phase 2
Request for collaborative review: WIRB serving as IRB of record.
1 - 10 of 18
- 1
- 2
